OSR Holdings Inc (OSRH) - Net Assets
Based on the latest financial reports, OSR Holdings Inc (OSRH) has net assets worth $127.04 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($171.24 Million) and total liabilities ($44.20 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore total assets of OSR Holdings Inc for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $127.04 Million |
| % of Total Assets | 74.19% |
| Annual Growth Rate | 913.82% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 19509.26 |
OSR Holdings Inc - Net Assets Trend (2020–2025)
This chart illustrates how OSR Holdings Inc's net assets have evolved over time, based on quarterly financial data. Check tangible net worth ratio of OSR Holdings Inc to evaluate the tangible quality of the company's equity base.
Annual Net Assets for OSR Holdings Inc (2020–2025)
The table below shows the annual net assets of OSR Holdings Inc from 2020 to 2025. For live valuation and market cap data, see OSR Holdings Inc (OSRH) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $127.04 Million | +2058.71% |
| 2024-12-31 | $-6.49 Million | -119.94% |
| 2023-12-31 | $32.52 Million | +41185.96% |
| 2022-12-31 | $78.77K | +3815.40% |
| 2021-12-31 | $-2.12K | -278.45% |
| 2020-12-31 | $1.19K | -- |
Equity Component Analysis
This analysis shows how different components contribute to OSR Holdings Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3714606900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.66K | 0.00% |
| Other Comprehensive Income | $3.84 Million | 4.94% |
| Other Components | $110.97 Million | 142.93% |
| Total Equity | $77.64 Million | 100.00% |
OSR Holdings Inc Competitors by Market Cap
The table below lists competitors of OSR Holdings Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
iRobot Corporation
NASDAQ:IRBT
|
$14.84 Million |
|
Zelan Bhd
KLSE:2283
|
$14.85 Million |
|
Diamyd Medical AB (publ)
ST:DMYD-B
|
$14.85 Million |
|
PeterLabs Holdings Bhd
KLSE:0171
|
$14.86 Million |
|
Biovica International AB (publ)
ST:BIOVIC-B
|
$14.81 Million |
|
IntegraFin Holdings plc
LSE:IHP
|
$14.81 Million |
|
Yuyu Pharma Inc
KO:000225
|
$14.81 Million |
|
Office Properties Income Trust
NASDAQ:OPI
|
$14.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in OSR Holdings Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -6,485,768 to 77,635,615, a change of 84,121,383.
- Net loss of 18,010,899 reduced equity.
- New share issuances of 4,796,471 increased equity.
- Other comprehensive income increased equity by 3,835,861.
- Other factors increased equity by 93,499,950.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-18.01 Million | -23.2% |
| Share Issuances | $4.80 Million | +6.18% |
| Other Comprehensive Income | $3.84 Million | +4.94% |
| Other Changes | $93.50 Million | +120.43% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares OSR Holdings Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.03x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2975.35x to 0.03x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $0.00 | $0.45 | x |
| 2021-12-31 | $0.00 | $0.45 | x |
| 2022-12-31 | $0.01 | $0.45 | x |
| 2023-12-31 | $4.21 | $0.45 | x |
| 2024-12-31 | $-1.45 | $0.45 | x |
| 2025-12-31 | $17.32 | $0.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently OSR Holdings Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -23.20%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -619.82%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 2.21x
- Recent ROE (-23.20%) is above the historical average (-345.21%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -2004.38% | 0.00% | 0.00x | 271.67x | $-23.93K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.10K |
| 2022 | -44.93% | 0.00% | 0.00x | 1.22x | $-43.26K |
| 2023 | 1.24% | 0.00% | 0.00x | 1.13x | $-2.85 Million |
| 2024 | 0.00% | -292.58% | 1.53x | 0.00x | $-9.68 Million |
| 2025 | -23.20% | -619.82% | 0.02x | 2.21x | $-25.77 Million |
Industry Comparison
This section compares OSR Holdings Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $128,838,508
- Average return on equity (ROE) among peers: -63.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| OSR Holdings Inc (OSRH) | $127.04 Million | -2004.38% | 0.35x | $14.84 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $143.70 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $9.08 Million | -66.39% | 1.81x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $-18.49 Million | 0.00% | 0.00x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-2.01 Million | 0.00% | 0.00x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $10.89 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-22.51 Million | 0.00% | 0.00x | $3.66 Billion |
About OSR Holdings Inc
OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Germany, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the… Read more